Addressing cortex dysregulation in youth through brain health check coaching and prophylactic brain development.
Brain health check
Cognition
Dopaminergic dysregulation
Epigenetics
Executive function
Genetics
Reward deficiency syndrome
Journal
INNOSC theranostics & pharmacological sciences
ISSN: 2705-0734
Titre abrégé: INNOSC Theranostics Pharmacol Sci
Pays: Singapore
ID NLM: 9918646272806676
Informations de publication
Date de publication:
30 Apr 2024
30 Apr 2024
Historique:
medline:
20
5
2024
pubmed:
20
5
2024
entrez:
20
5
2024
Statut:
ppublish
Résumé
The Carter Center has estimated that the addiction crisis in the United States (US), if continues to worsen at the same rate, may cost the country approximately 16 trillion dollars by 2030. In recent years, the well-being of youth has been compromised by not only the coronavirus disease 2019 pandemic but also the alarming global opioid crisis, particularly in the US. Each year, deadly opioid drugs claim hundreds of thousands of lives, contributing to an ever-rising death toll. In addition, maternal usage of opioids and other drugs during pregnancy could compromise the neurodevelopment of children. A high rate of DNA polymorphic antecedents compounds the occurrence of epigenetic insults involving methylation of specific essential genes related to normal brain function. These genetic antecedent insults affect healthy DNA and mRNA transcription, leading to a loss of proteins required for normal brain development and function in youth. Myelination in the frontal cortex, a process known to extend until the late 20s, delays the development of proficient executive function and decision-making abilities. Understanding this delay in brain development, along with the presence of potential high-risk antecedent polymorphic variants or alleles and generational epigenetics, provides a clear rationale for embracing the Brain Research Commission's suggestion to mimic fitness programs with an adaptable brain health check (BHC). Implementing the BHC within the educational systems in the US and other countries could serve as an effective initiative for proactive therapies aimed at reducing juvenile mental health problems and eventually criminal activities, addiction, and other behaviors associated with reward deficiency syndrome.
Identifiants
pubmed: 38766548
doi: 10.36922/itps.1472
pmc: PMC11100020
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1472Déclaration de conflit d'intérêts
Conflict of interest KENNETH BLUM is the holder of both USA and foreign patents related to kb220 and gars. Other authors declare no conflicts of interest.